These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35459359)

  • 1. Cardiovascular prevention: early and consistent prevention versus late intervention, complex approach to the treatment of modifiable risk factors: hypertension and dyslipidemia.
    Zlatohlávek L
    Vnitr Lek; 2021; 67(7):412-418. PubMed ID: 35459359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering therapy: who can benefit?
    Lewis SJ
    Vasc Health Risk Manag; 2011; 7():525-34. PubMed ID: 21915170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical implications and management of concomitant hypertension and dyslipidemia.
    Nash DT
    Postgrad Med; 2006; 119(2):37-45. PubMed ID: 16961051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of the metabolic syndrome.
    Ceska R
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S2-4. PubMed ID: 17935057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are pediatricians responsible for prevention of adult cardiovascular disease?
    McGill HC; McMahan CA; Gidding SS
    Nat Clin Pract Cardiovasc Med; 2009 Jan; 6(1):10-1. PubMed ID: 18957957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice.
    Filipiak KJ; Babkowski MC; Cameli M; Carugo S; Ferri C; Irisov DB; Narkiewicz K; Nizamov U; Pérez de Isla L; Tomaszuk-Kazberuk A; Ungar A; Gąsecka A
    Cardiol J; 2022; 29(5):730-738. PubMed ID: 36117294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Euvascor - early intervention of hypertension and dyslipidaemia (dual combination of atorvastatin and perindopril).
    Zlatohlávek L
    Vnitr Lek; 2020; 66(3):190-195. PubMed ID: 32972174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
    Kotake H; Oikawa S
    Nihon Rinsho; 2006 Nov; 64(11):2074-80. PubMed ID: 17087299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?
    Roever L; Biondi-Zoccai G; Rao SV
    Clin Ther; 2017 Mar; 39(3):659-660. PubMed ID: 28190598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated control of hypertension, dyslipidemia and carotid atherosclerosis in the reduction of cardiovascular risk.
    Riccioni G
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):371-4. PubMed ID: 17489661
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
    Berman AN; Blankstein R
    Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [2018 new recommendations for dyslipidemia : a critical review of evidence].
    Aubert CE; Rodondi N
    Rev Med Suisse; 2018 Feb; 14(596):456-460. PubMed ID: 29489125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Disease Risk in Children With Kidney Disease.
    Sethna CB; Merchant K; Reyes A
    Semin Nephrol; 2018 May; 38(3):298-313. PubMed ID: 29753405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
    Lonn E; Grewal J
    Curr Vasc Pharmacol; 2006 Jul; 4(3):253-68. PubMed ID: 16842143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [News in the treatment of hypertension and dyslipidemia].
    Václavík J
    Vnitr Lek; 2017; 63(5):333-337. PubMed ID: 28726432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for a combined approach to the management of hypertension and dyslipidemia.
    Ansell BJ
    Am J Hypertens; 2005 Sep; 18(9 Pt 1):1249-57. PubMed ID: 16245413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
    Kushiro T; Mizuno K; Nakaya N; Ohashi Y; Tajima N; Teramoto T; Uchiyama S; Nakamura H;
    Hypertension; 2009 Feb; 53(2):135-41. PubMed ID: 19104004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive approach to a patient with arterial hypertension and dyslipidemia.
    Ramík Z; Václavík J; Jadrníčková P; Obrová J; Stromská J
    Vnitr Lek; 2022; 68(6):376-386. PubMed ID: 36316199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
    Watanabe T
    Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.